Drugdiscovery >> Drugs >> News
5220
Views
title
Perjeta approved for early breast cancer - drugdiscovery.com


The FDA has granted accelerated approval to Roche's Perjeta (pertuzumab) as part of a complete treatment regimen for patients with HER2-positive, locally advanced, inflammatory or early stage breast cancer before surgery . This is the first FDA-approved drug for the neoadjuvant treatment of breast cancer.
Read More >>


Tags: Perjeta, pertuzumab, Roche, FDA, approval, early breast cancer, inflammatory breast cancer, neoadjuvant, treatment - October 1, 2013
Related Articles
2091
Views
FDA panel recommends Perjeta for neoadjuvant use in early breast cancer FDA panel recommends Perjeta for neoadjuvant use in early breast cancer
With FDA’s aim to get cutting-edge treatments to early-stage patients in hopes of stopping the disease in its tracks, Roche’s Perjeta is on its way to get a new indication for the treatment of pat Read More >>

Tags: Perjeta, early breast cancer, HER2-positive, neoadjuvant, before surgery

5479
Views
A positive review of  Roche’s  Perjeta in early stage breast cancer A positive review of Roche’s Perjeta in early stage breast cancer
The FDA has issued a positive review of Perjeta and recommended accelerating approval. In mid-stage trials, women with early-stage breast cancer who received the drug had significantly fewer tumor Read More >>

Tags: Perjeta, Roche, breast cancer, early stage, FDA, review

5137
Views
The growth of breast cancer market in the future The growth of breast cancer market in the future
According to findings from Decision resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, the breast cancer market will grow to more than $15 bil Read More >>

Tags: breast cancer, drugs, market, perjeta, afinitor, herceptin, palbociclib

2722
Views
Perjeta’s benefits questioned Perjeta’s benefits questioned
Cinical data presented to NICE's independent appraisal committee left unclear how long Roche's Perjeta (pertuzumab) might extend patient’s lives, yet it costs much more than current NHS treatme Read More >>

Tags: Perjeta, Roche, NHS, NICE, advanced breast cancer

5444
Views
Eisai’s breast cancer drug launched in Russia Eisai’s breast cancer drug launched in Russia
Halaven (eribulin mesylate), a novel anticancer agent developed by Eisai, has now been launched in Russia, where it is approved for the treatment of locally advanced or metastatic breast cancer previo Read More >>

Tags: Eisai, halaven, eribulin mesylate, breast cancer, Russia

4195
Views
Decitabine could help treat breast cancer Decitabine could help treat breast cancer
Decitabine is currently licensed for the treatment of acute myeloid leukaemia. It is one of the rare, FDA approved cancer drugs, that work as DNA methylation modifiers. The results of an animal study Read More >>

Tags: decitabine, breast cancer, study, leukaemia, acute myeloid leukaemia, epigenetics, methylation, PRKD1

2386
Views
Tamoxifen may prevent breast cancer Tamoxifen may prevent breast cancer
The results of the largest to date global study suggest that women who carry the BRCA1 or BRCA2 mutation which put them at high risk of developing breast cancer could benefit from taking tamoxifen fo Read More >>

Tags: Tamoxifen, breast cancer, prevention, BRCA 1, BRCA 2, mutation, high risk

5286
Views
Femara beneficial for breast cancer patients treated with tamoxifen Femara beneficial for breast cancer patients treated with tamoxifen
The results of a large study show that femara significantly reduces the risk of breast cancer reccurence in patients who were treated both drugs. Read More >>

Tags: breast cancer, femara, tamoxifen, risk, recurrence

4941
Views
Long-term calcium-channel blocker therapy linked to increased breast cancer risk Long-term calcium-channel blocker therapy linked to increased breast cancer risk
A case-control study showed that the risk of breast cancer more than doubled in postmenopausal women who were on a long-term calcium- channel blocker therapy. Women who were on other types of heart dr Read More >>

Tags: calcium-channel blocker,long-term therapy, breast cancer, diuretics, beta-blockers, ACE inhibitors, or angiotensin receptor blockers

5559
Views
Gilotrif Approved for Late-Stage Lung Cancer Gilotrif Approved for Late-Stage Lung Cancer
The U.S. Food and Drug Administration approved Gilotrif (afatinib) for patients with late stage (metastatic) non-small cell lung cancer (NSCLC) whose tumors express specific types of epidermal growth Read More >>

Tags: Gilotrif, metastatic non-small cell lung cancer

MOST VIEWED
HOME | ABOUT | PRIVACY POLICY | TERMS & CONDITIONS | ADVERTISE | CONTACT
All rights reserved drugdiscovery.com 2013